HLA-B*5701 screening implications

The main benefit of screening, regardless of race, is that it identifies the majority of the population to whom it is safe to administer abacavir. Although screening necessarily excludes some patients from abacavir therapy who would have tolerated the drug, this is compensated by the fall in false positive clinical diagnoses achieved in an open screening population.